Indian J Physiol Pharmacol 2007 512Aspirin Resistance111and COX2 expression or a novel platelet biosynthesis which would remain from cells in the 112Ashwin et alIndian J Physiol Pharmacol 2007 ID: 937754
Download Pdf The PPT/PDF document "110Ashwin et alIndian J Physiol Pharma..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
110Ashwin et alIndian J Physiol Pharmacol 2007; 51(2)combined outcome of any serious vascularheart attack or stroke. Also, 1 in 10none of the mutations were located near theconcluded that aspirin resistance expressedplatelet COX-2. COX-2 is 170-fold less Indian J Physiol Pharmacol 2007; 51(2)Aspirin Resistance111and COX-2 expression or a novel platelet biosynthesis which would remain from cells in the 112Ashwin et alIndian J Physiol Pharmacol 2007; 51(2)completely suppressing the biosynthesis
of in normal subjects and indaily, although a small difference may haveEvidence supports the choice of a dailytablets of 75 to 100 mg) when immediateor crescendo transient cerebral ischemicserum cholesterol or LDL cholesterol and Indian J Physiol Pharmacol 2007; 51(2)Aspirin Resistance113in people with diabetes. Diabetic plateletsin platelet thrombus formation afterIn terms of laboratory assays, aspirin has 114Ashwin et alIndian J Physiol Pharmacol 2007; 51(2)newer assays include the following
: has generation. The assay requires 10 Indian J Physiol Pharmacol 2007; 51(2)Aspirin Resistance115third, and fourth quartiles appeared to beAlthough several studies havea study by Lev et al (43), which was done in 116Ashwin et alIndian J Physiol Pharmacol 2007; 51(2)1.Mueller RL, Scheidt S. History of drugs for 1994; 89(1): 1994; 308:3.Antithrombotic trialists collaboration.4.Hurlen M, Seljeflot I, Arnesen H. The effect of 1998; 32(4): 233237.5.Tarjan J, Salamon A, Jager R, Poor F, Barcoziun
dergoing secondary salicylic acid prophylaxis6.Andersen K, Hurlen M, Arnesen H, Seljeflot I. 2002;7.McCabe DJ, Harrison P, Mackie U, Sidhu PS, 2005; 16(5): 269280.8.Grotemeyer KH, Scharafinski HW, Hussteat IW. 1993; 71(5):9.Grundmann K, Jaschonck K, Kleine B, Dichgans 2003; 250(1): 6366.10.Eikelboom JW, Hirsh J, Weitz JI, Johnston M,Yi Q, Yusuf S. Aspirin resistant thromboxane11.Buchanan MR, Schwartz L, Bourassa M, Brister 2000;12.Kranzhofer R, Ruef J. Aspirin resistance in13.Gum PA, Kottke-Ma
rchant K, Welsh PA, White 2003; 41(6): 961965.14.Hillarp A, Palmavist B, Lethagen S, Villoutreix 2003;15.Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y,16.Zimmermann N, Wenk A, Kim U, Kienzle P, 2003; 108(5): 542547.17.Szczeklik A, Undas A, Sanak M, Frolow M, 2000;18.McAdam BF, Byrne D, Morrow JD, Gates JA.biosynthesis of thromboxane A2 and19.Harrison P, Mackie I, Mathur A, Robinson MS, 2005; 16(8): 557562.20.Catella-Lawson F, Reilly MP, Kapoor SC,Cyclooxygenase inhibitors and the antiplatelet In
dian J Physiol Pharmacol 2007; 51(2)Aspirin Resistance11721.Patrono C. Aspirin as an antiplatelet drug. 1994; 330(18): 12871294.22.Szczeklik A, Musial J, Undas A, Swadzba J, Gora 1996; 16: 948954.23.Mehta SS, Silver RJ, Aaronson A, Abrahamson24.Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin25.De Schryver ELLM, Van Gijn J, Kappelle LJ, 2005; 252:26.Dussaillant NG, Zapata MM, Fardella BP, Conte 2005; 133(4): 409417.27.Mirkhel A, Peyster E, Sundun J, Greene L, 2006; 98(5): 577579.28.Hung J, La
m JYT, Lacoste L, Letchacovski G. 1995;29.Feng DL, Murillo J, Jadhav P, McKenna C, 1999; 33(6): 401404.30.Pamuken B, Oflaz H, Acar RD, Umman S, Koylan 2005; 20(1): 1722.31.Cox D, Maree AO, Dooley M, Conroy R, Byrne 2006; 37(8): 21532158.32.Karha J, Rajagopal V, Kottke-Marchant K, Bhatt 2006; 51(5): 976.33.Lehman CM, Blaylock RC, Alexander DP,34.De Gaetano G, Cerletti C. Aspirin resistance: a 2003; 1: 20482050.35.Jilma B. Platelet function analyzer (PFA-100): atool to quantify congenital or a
cquired platelet 2001; 138(3): 15236.Accumetrics Inc. VerifyNow (aspirin assay) 2004.37.Coleman J, Wang JC, Simon JI. Determination38.Chen WH, Lee P, Ng W, Tse H, Lau C. Aspirin 2004 ;43: 112239.Curtis JP, Wang Y, Portnay EL, Masoudi FA, 2003; 327: 132240.Eikelboom JW, Hirsh J, Weitz JI, Johnston M, 2002; 105: 16501655.41.Bhat DL, Fox KA, Hacke W, Berger PB, Black42.Eikelboom JW, Hankey GJ, Thorn J, Claxton A, 2005; 3(12): 264943.Lev El, Patel RT, Maresh KJ, Guthikonda S, 2006;44.Matetzky S
, Shenkman B, Guetta V, Shechterresistance is associated with increased risk of Indian J Physiol Pharmacol 2007; 51(2): 109117*Corresponding Author :Dr. K. L. Bairy, Professor of Pharmacology, Kasturba Medical College,Manipal 576 104; Phone No.: 0091820 2570188; Fassimile No.: 0820 2571999;E-mail address: klbairy@yahoo.com*, SUDHA VIDYASAGAR(Received on February 20, 2007) Aspirin reduces the odds of serious atherothrombotic vascularaspirin remains the single most cost-effective drug for the se